Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192630 | 0.83 | AGXT (0.47) | AGXT | |
| SCHEMBL191418 | 0.75 | AGXT (0.45) | AGXT | |
| SCHEMBL3799319 | 0.75 | AGXT (0.46) | AGXT | |
| SCHEMBL18784708 | 0.74 | BACE1 (0.30) | — | |
| SCHEMBL3797818 | 0.73 | AGXT (0.44) | AGXT | |
| SCHEMBL24814031 | 0.72 | — | — | |
| SCHEMBL18393602 | 0.72 | CA2 (0.38) | — | |
| SCHEMBL29950898 | 0.72 | AGXT (0.32) | AGXT | |
| SCHEMBL28878932 | 0.72 | AGXT (0.32) | AGXT | |
| SCHEMBL30835718 | 0.72 | PLAU (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | AGXT 3394/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | AGXT 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.